Explore the substrate
Search everything we hold — entities, source-backed facts, the conclusions we’re drawing, and the sources behind them. Type a topic, not just a claim. How we source →
22 items across the substrate for “drug discovery”
What we're concluding
8AI Foundation Models Become the New Infrastructure Layer for Drug Discovery
A wave of AI-native platforms and foundation models (NVIDIA BioNeMo, MindWalk's HYFT/ReefIQ, Basecamp's EDEN, Edison's Kosmos, Owkin's OwkinZero, Boltz Lab) is being built out across pharma and biotech R&D, anchored by NVIDIA's hardware partnerships with Thermo Fisher and Lilly and reinforced by MindWalk's move to patent-protect its biological data representation layer. Financial strength at Novo Nordisk (accelerating stock gains, solid Q1 earnings) is coinciding with a strategic pivot away from owning cell therapy manufacturing in-house toward licensing it out to AI-driven specialists like Cellular Intelligence, suggesting capital and R&D focus are rotating toward AI-native platforms rather than traditional biotech infrastructure.
Bio-Native AI Infrastructure Race: NVIDIA-Anchored Platforms, Pharma Restructuring, and Proprietary Data Architectures
AI-for-drug-discovery is shifting from standalone models toward integrated infrastructure. NVIDIA's BioNeMo ecosystem and its lab partnerships with Lilly and Thermo Fisher anchor one side, and a wave of agentic and foundation-model launches (Owkin, Edison, Basecamp, Boltz, Natera, MindWalk's ReefIQ) fills out the field. Big pharma is restructuring around the shift: Novo Nordisk closed its internal cell therapy unit and out-licensed its Parkinson's program to the AI platform Cellular Intelligence, while its stock rallied after Q1 2026 earnings. Smaller players are defending their position with IP, such as MindWalk's European patent on a high-dimensional biological data architecture, arguing that the data representation of biology, not model size, is the real bottleneck.
Pharma Hands Drug Discovery to AI Platforms: NVIDIA's BioNeMo Ecosystem, Agentic Research Tools and Data-Architecture IP
Since January 2026, drug discovery has been shifting toward AI-native infrastructure. NVIDIA is the hub: BioNeMo expanded, with lab-in-the-loop partnerships with Lilly and Thermo Fisher. Startups are launching biology foundation models and research agents (Boltz, EDEN, Kosmos, OwkinZero, Bionic Intelligence). Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to the AI-platform company Cellular Intelligence, while its stock rose about 25% over 30 days. MindWalk's July European patent filing on a biological data architecture shows the competition moving to proprietary data representation and IP.
AI Foundation Models Go Bio-Native: Chipmakers, Pharma, and Startups Race to Own the Drug-Discovery Stack
Starting in January 2026, NVIDIA's BioNeMo platform anchored a wave of lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, catalyzing a broader surge of bio-native AI platform launches (MindWalk's HYFT/ReefIQ, Natera, Boltz Lab, Owkin, Edison Scientific) through mid-2026, with MindWalk now moving to patent its underlying biological data representation. In parallel, established pharma is restructuring around this shift: Novo Nordisk closed its internal cell therapy unit and licensed the program out to the AI-native Cellular Intelligence, even as its stock rallied nearly 25% in 30 days on strong Q1 earnings — signaling investor confidence that AI-driven drug discovery infrastructure, not in-house R&D, is where value is consolidating.
Foundation-Model Platforms and Pharma Partnerships Converge on AI-Native Drug Discovery
Biotech AI is shifting from standalone models to integrated infrastructure: NVIDIA's BioNeMo, lab-in-the-loop collaborations with Lilly and Thermo Fisher, and a wave of foundation-model and agent launches (EDEN, Boltz Lab, OwkinZero, Kosmos, Researgent 2.0, Natera). Incumbents are reorganizing around this. Novo Nordisk closed its internal cell therapy unit and licensed its Parkinson's program to Cellular Intelligence, while MindWalk is building IP moats around biological data representation (HYFT, a new EP application). Markets have been receptive, with Novo's stock up about 25% in 30 days around its Q1 2026 earnings, though the evidence for AI-driven revenue is still thin and the claims are mostly company-promotional.
Oncology's Late-Stage Catalyst Wave Meets AI-Driven Drug Discovery and Sector Consolidation
Oncology is in a dense Q4 2026 catalyst window. The FDA approved Tecentriq in adjuvant dMMR colon cancer and set a PDUFA date of 2026-11-14 for ivonescimab. Personalized mRNA vaccines (intismeran) and bispecific, ADC and protein-degrader combinations (ivonescimab plus Datroway, bexobrutideg) are advancing alongside new trial collaborations. At the same time, AstraZeneca executives describe AI-designed biologics and automated labs as the next productivity lever, and McKesson/CD&R's Option Care Health acquisition and Novocure's record quarter show capital moving into oncology services and commercial delivery.
Oncology's ESMO 2026 Catalyst Wave: ADC Momentum, Regulatory Wins and AI-Driven Discovery
Oncology is heading into ESMO 2026 (Oct 23-24) with strong regulatory momentum: positive CHMP opinions for RASONQUE and the updated Libtayo dosing, and an FDA approval for Tecentriq in dMMR colon cancer. Antibody-drug conjugates are the main investment theme. AbbVie is presenting a broad ADC portfolio, Akari is positioning for ADC-refractory patients, and Summit, AstraZeneca and Daiichi Sankyo have a new trial collaboration. Meanwhile, big pharma such as AstraZeneca is pushing AI-enabled, robotics-run 'lab of the future' discovery, and commercial and M&A signals (Novocure's record quarter, McKesson/CD&R buying Option Care Health) point to growing capital flow into the sector.
ESMO 2026 Catalyst Wave: Oncology Regulatory Wins and AI-Driven Drug Discovery Converge
October 2026 brings a cluster of oncology catalysts. Positive CHMP opinions (RASONQUE in pancreatic cancer, an updated Libtayo regimen), an FDA approval (Tecentriq in adjuvant dMMR colon cancer) and heavy ESMO data from AbbVie, intismeran and others support a constructive sector tone. Meanwhile AstraZeneca's AI-enabled 'lab of the future' and agentic biologics design, plus ADC-focused small caps like Akari and consolidation such as McKesson/CD&R's Option Care Health deal, point to capital and talent moving toward AI-accelerated, ADC-centred oncology pipelines.
Source-backed facts
6drug_approvals: 17 drugssources differ
drug_approvals: 46 novel_drugs (Q4 2025)
drug_approvals: 50 novel_drugs (Q4 2024)
Sources we've traced
8As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
AI in Genomics Market Research and Global Forecast Report 2026-2040 - Machine Learning-Driven Drug Discovery and Strategic Tech-Pharma Collaborations Fuel Growth
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery
Stellora.AI Advances Quantum Flow to Support Healthcare, Drug Discovery, and Disease Research